NIH will study home treatment of COVID-19 with repurposed drugs

This week, the National Institutes of Health (NIH) announced it will begin a Phase 3 clinical trial, dubbed ACTIV-6, to evaluate whether seven drugs approved for other conditions might be used to safely and effectively treat mild-to-moderate COVID-19 in the home. The NIH is focused on enrolling patients in minority, rural and other communities significantly affected by COVID-19. Each of the drugs used in the ACTIV-6 trial may be taken orally or inhaled and showed promise in smaller trials. (NIH news release, 4/19/21)